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INTRODUCTION
Microscopic polyangiitis (MPA) is a systemic vasculitis his-
tologically characterized by pauci-immune necrotizing small-
vessel vasculitis without granulomatous inflammation. MPA
was initially recognized as a microscopic form of polyarteri-
tis nodosa (PAN), accompanied by rapidly progressive necro-
tizing glomerulonephritis (RPGN) and, in some cases, lung
hemorrhage (1).
In Korea, several case reports have been published on pati-
ents with MPA, but there have been no studies describing the
clinical features and treatment outcomes of MPA in Korean
patients. This retrospective study assessed the clinical mani-
festations and outcomes of MPA in Korean patients.
MATERIALS AND METHODS
We retrospectively reviewed the medical records of 18 pati-
ents diagnosed as having MPA at Asan Medical Center, Uni-
versity of Ulsan College of Medicine, Seoul, Korea, between
1989 and 2006. Diagnoses were based on the Chapel Hill con-
sensus conference (CHCC) definition of MPA (1994) (2). In
13 of the 18 patients, MPA diagnosis was confirmed histo-
logically by renal biopsy.
To classify MPA in Korean patients and compare results
with those of other studies, we applied the inclusion criteria
used in a large study of MPA (3), consisting of 1) presence
of RPGN and/or alveolar hemorrhage; 2) histologic demon-
stration of small-sized vessel vasculitis or segmental pauci-
immune necrotizing glomerulonephritis (GN); and/or 3)
symptoms suggesting small-vessel involvement (e.g., pur-
pura) without GN and/or alveolar hemorrhage. 
Only patients with systemic vasculitis were included; pati-
ents with other small-vessel vasculitides, such as Wegener’s
granulomatosis, or other connective tissue disease-associated
vasculitis, were excluded from this study. Antineutrophil cyto-
plasmic antibodies (ANCA) were not included as a criterion.
For each patient, the following data were recorded: gender,
age, clinical features, laboratory and immunologic parameters
at time of diagnosis, treatment, outcome, duration of follow-
up, and cause of death. The clinical features included symp-
toms, signs and organ involvement at presentation and dur-
ing follow-up. Laboratory parameters included white blood
cell (WBC) and platelet counts, hemoglobin, erythrocyte sed-
imentation rate (ESR), C-reactive protein (CRP), creatinine,
liver enzymes, and hematuria and proteinuria on urinalysis.
Immunologic parameters included the presence of antinuclear
antibody (ANA), ANCA, rheumatoid factor (RF), comple-
ment components C3 and C4, hepatitis B virus (HBV) sur-
face antigen (HBsAg) and antibody (anti-HBs), HBV core
antibody (anti-HBc), and anti-hepatitis C virus antibody
(anti-HCV).
To evaluate the association between disease activity at time
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Clinical Features and Outcomes of Microscopic Polyangiitis in Korea
Microscopic polyangiitis (MPA) is a systemic vasculitis affecting small vessels. To
determine the clinical features and outcomes of MPA in Korean patients, we retro-
spectively reviewed the medical records of patients diagnosed with MPA at a single
medical center in Korea between 1989 and 2006. The 18 patients who met the Cha-
pel Hill criteria for MPA had a mean (±SD) age at the time of diagnosis of 62.4±
12.7 yr. Renal manifestations and general symptoms were the most common fea-
tures of MPA, with lung involvement also very common. Antineutrophil cytoplasmic
antibodies (ANCA) were present in 17 of the 18 patients (94%). Of 17 patients treat-
ed with steroids and cyclophosphamide, 11 (65%) had stable or improved course.
One patient treated with steroids without cyclophosphamide showed disease pro-
gression. Ten of the 18 patients (56%) died at a median follow-up of 8 months.
MPA in Korean patients was distinguished by a higher rate of lung involvement, espe-
cially alveolar hemorrhage, which was the leading cause of death in our patients.
Korean patients were also older at MPA onset and were more likely positive for
ANCA. Other overall clinical manifestations did not differ significantly.
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Accepted : 22 June 2008of diagnosis and outcome, we retrospectively applied the Five
Factor Score (FFS) (4) and the Birmingham Vasculitis Activ-
ity Score (BVAS) (5) at the time of diagnosis. The FFS consists
of proteinuria (>1 g/day), renal insufficiency (serum creatinine
>1.58 mg/dL), severe gastrointestinal (GI) tract involvement
(defined as bleeding, perforation, infarction, and/or pancre-
atitis), cardiomyopathy, and/or central nervous system (CNS)
involvement, with the presence of each factor accorded 1 point.
The BVAS is a clinical index of disease activity based on symp-
toms and signs in 9 separate organ systems; the maximum
score is 63.
Treatment response was defined as the stabilization or atten-
uation of clinical symptoms, signs and laboratory abnormal-
ities after initiation of treatment. Relapses were defined as
new systemic manifestations of vasculitis or worsening of 1
or several of the initial manifestations of the disease.
Causes of death were classified into 3 subgroups: vasculitis-
related, vasculitis-unrelated such as treatment side effects, and
unknown.
Long-term survival of patients was determined by trying
to contact patients or their first-degree relatives. 
Kaplan-Meier life survival analysis and the log-rank test
were used to assess patient survival and to compare survival
relative to FFS, BVAS, age and presence of alveolar hemor-
rhage.
RESULTS
Clinical features
Of the 18 patients, 9 were men and 9 were women; their
mean (±SD) age at the time of diagnosis was 62.4±12.7
yr (range, 22-83 yr), and the median duration of follow-up
was 8 months (range, 0-108 months). Mean (±SD) time to
diagnosis from the onset of symptoms was 1.9±2.4 months
(range, 0.2-10 months). Clinical manifestations at the time
of diagnosis and during the course of the disease are summa-
rized in Table 1. Renal manifestations (n=18, 100%) and
various general symptoms (n=18, 100%) were the most com-
mon features of MPA. Lung involvement was seen in 13 pati-
ents (72%). Other manifestations included peripheral neu-
ropathy (n=7, 39%), skin rash (n=6, 33%), musculoskeletal
pain (n=6, 33%), gastrointestinal involvement (n=5, 28%)
and cardiac involvement (n=4, 22%).
Laboratory findings
At the time of admission, mean (±SD) WBC and platelet
counts were 13.7±5.3×10
3/μ L and 316±128×10
3/μ L,
respectively. Mean (±SD) levels of hemoglobin, ESR, CRP
and creatinine were 8.6±1.8 g/dL, 71±40 mm/hr, 11.4±
5.7 mg/dL, and 4.2±3.0 mg/dL, respectively.
At admission, 14 patients (77%) had renal insufficiency
(creatinine >1.4 mg/dL), 16 (89%) had hematuria (>1+), and
11 (61%) had proteinuria (>1+). During the course of the
disease, however, all patients had renal insufficiency (100%)
and proteinuria (100%), and 17 patients (94%) had hema-
turia. Nine of 16 patients (56%) in whom 24 hr urine col-
lection was performed had proteinuria >1 g per day, a com-
ponent of the FFS.
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*Indicates a factor of the Five Factor Score. 
RBC, red blood cell; CNS, central nervous system.
Number (%)
General symptoms 18 (100)
Fever 14 (78)
Malaise 10 (56)
General myalgia 5 (28)
Weight loss 4 (22)
Musculoskeletal 6 (33)
Arthralgia 5 (28)
Muscle pain 2 (11)
Skin rash 6 (33)
Ear, nose and throat 3 (17)
Gastrointestinal (GI) 5 (28)
Abnormal liver function 1 (6)
Severe GI involvement* 3 (17)
Cardiac 4 (22)
Pericarditis 3/8 (38)
Cardiomyopathy or heart failure* 1 (6)
Pulmonary 13 (72)
Alveolar hemorrhage  7 (39)
Pleural effusion 4 (22)
Infiltration or nodule 1 (6)
Renal 18 (100)
Azotemia (>1.58 mg/dL)* 18 (100)
Proteinuria (>1+ or >0.2 g/24 hr) 18 (100)
Hematuria (>1+) 17 (94)
Proteinuria (>1 g/24 hr)* 9/16 (56)
Neurologic 7 (39)
Peripheral neuropathy 7 (39)
CNS involvement* 1 (6)
Table 1. Clinical manifestations of microscopic polyangiitis at the
time of diagnosis and during the course of disease
HBsAg, hepatitis B surface antigen; Anti-HBs, hepatitis B surface anti-
body; Anti-HBc, hepatitis B core antibody; Anti-HCV, hepatitis C virus anti-
body.
Number (%)
Antineutrophil cytoplasmic antibody 17 (94)
Antinuclear antibody 7 (38)
Rheumatoid factor 4 (22)
C3 (decreased level) 6 (33)
C4 (decreased level) 2 (11)
HBsAg 0 (0)
Anti-HBs 13 (72)
Anti-HBc 5 (27)
Anti-HCV 2 (11)
Table 2. Immunologic parameters at the time of diagnosisANCA were determined by enzyme linked immunosorbent
assay (ELISA) in 17 of the 18 patients, and by an immunoflu-
orescence (IF) assay alone in one patient. Myeloperoxidase
(MPO)-ANCA was positive in 16 of the 17 patients in whom
ELISA was performed, whereas proteinase-3 (PR-3)-ANCA
was not detected in any patient (Table 2). In the one patient
for whom immunofluorescence (IF) assay was performed, per-
inuclear ANCA was detected. Thus, ANCA were found to
be present in 17 of the 18 patients (94%). 
Other relatively common features at the time of diagnosis
were presence of ANA (n=7, 38%), decreased level of C3 (n=
6, 33%), and presence of rheumatoid factor (n=4, 22%).
Treatment, outcome and prognostic factors
Of the 18 patients, 17 (94%) were treated with a combi-
nation of steroids and cyclophosphamide. Cyclophosphamide
was administered orally in 12 patients and intravenously in
5 patients. Of the 17 patients treated with steroids and cyclo-
phosphamide, 11 (65%) showed stable disease or improve-
ment. One patient with diffuse alveolar hemorrhage (DAH)
who was treated with pulse steroid therapy plus plasmaphere-
sis died within 10 days of the onset of DAH. All 7 patients
with DAH were treated with additional plasmapheresis, but
5 (71%) showed aggravation of DAH independent of initial
response to treatment. Overall, 11 of the 18 patients (61%)
showed response to treatment.
Of the 18 patients, 9 (50%) underwent dialysis, but only
one became dialysis-independent. Mean creatinine level decr-
eased after treatment, with or without permanent dialysis
(Table 3).
Ten of the 18 patients (56%) died, with 6 deaths related
to vasculitis and 2 deaths related to infections such as pneu-
monia and sepsis. DAH (50%) was the most common cause
of vasculitis-related death. We could not confirm the cause
of death in 2 patients who were lost to follow-up (Table 4).
Five of the 18 patients (28%) relapsed during the follow-
up period, with 3 patients showing new systemic manifesta-
tions of vasculitis and the other 2 exhibiting worsening of
their initial manifestations. Organs involved at the time of
relapse included the kidneys, CNS, GI, heart, and lungs. Medi-
an time to relapse was 1.4 months. Of the 5 patients who
relapsed, 3 (60%) died.
Overall mortality of MPA was 56%. Survival rates at 1 and
3 yr were 56% and 43%, respectively. Mean and median sur-
vival times were 53 months and 32 months, respectively
(Fig. 1).
Mean FFS at the time of diagnosis was 1.44 (range, 0-2) and
mean BVAS was 19.5 (range, 9-31). Survival curves accord-
ing to FFS, BVAS, age and presence of DAH are shown in
Fig. 2.
DISCUSSION
MPA was first recognized as a separate disease entity in
1948 in a subgroup of PAN patients with renal involvement
characterized by segmental necrotizing GN (1). The clinical
manifestations of MPA are very similar to those of PAN, but
are characterized by the presence of RPGN and pulmonary
capillaritis. In 1992, the term microscopic polyangiitis was
adopted to connote a necrotizing vasculitis with few or no
immune complexes affecting small vessels (capillaries, venules,
and/or arterioles) (2), with MPA distinguished from PAN by
the presence of small-vessel involvement. Because both MPA
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Creatinine level, mean±SD (mg/dL)
Before After  treatment
treatment (at the end of follow-up)
All patients (n=18) 5.0±2.9 2.9±2.6
Without permanent  3.6±2.1 2.1±1.3
dialysis (n=10)
Table 3. Creatinine level before and after treatment
Number (%)
Vasculitis-related 6 (60)
Alveolar hemorrhage 5 (50)
Gastrointestinal hemorrhage 1 (10)
Vasculitis-unrelated 2 (20)
Pneumonia 1 (10)
Sepsis (other than pneumonia) 1 (10)
Drug side effect (other than infection) -
Other comorbidity -
Unknown (follow-up loss) 2 (20)
Table 4. Causes of death in patients with microscopic polyangi-
itis (n=10)
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Fig. 1. Kaplan-Meier survival curve for the 18 patients with micro-
scopic polyangiitis.and Wegener’s granulomatosis involve the small vessels, they
share similar clinical features, such as DAH and GN; how-
ever, granulomatous inflammation is absent from MPA, dif-
ferentiating it from Wegener’s granulomatosis.
The overall clinical manifestations and disease courses in
our patients were similar to those reported in other studies
(Table 5). In contrast, while previous studies reported that
MPA affects men slightly more often than women, we found
a male:female ratio of 1:1. In addition, the mean age at the
time of diagnosis in our patients was 63 yr, which is older
than in previous reports.
Renal manifestations were the most predominant features
of MPA in our patients. While renal insufficiency occurred
in all patients during the course of disease, dialysis was required
by only 50% of patients. In contrast, 25% to 45% of pati-
ents in previous studies required dialysis (6, 7).
DAH is the most serious form of lung involvement in MPA,
reported in 12% to 29% of patients in several series (3, 6).
We found, however, that pulmonary manifestations, especially
DAH, were more frequent and severe in our patients. In con-
trast, involvement of the skin, GI tract and musculoskeletal
system was less frequent in our patients than in previous re-
ports, whereas cardiac manifestations, including pericardial
effusion and cardiomyopathy, were more common.
Previous studies have reported that 50% to 80% of MPA
patients are positive for ANCA (8-10). In one study, ANCA
were present in 74.5% of patients at the time of diagnosis;
among them, 87% had a perinuclear staining pattern (pAN
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Fig. 2. Kaplan-Meier survival curves for the 18 patients with microscopic polyangiitis relative to (A) Five-Factor Score (p not significant),
(B) Birmingham Vasculitis Activity Score (p=0.1), (C) age (p=0.16), and (D) presence or absence of alveolar hemorrhage (p=0.0016). Data
were analyzed using the log-rank test.CA) and 13% had a cytoplasmic pattern (cANCA) (3). We
found that 94% of our patients were positive for ANCA; of
these, all had pANCA.
We found that 89% of our MPA patients also met the
American College of Rheumatology (ACR) criteria for PAN
(11), which include the presence of HBsAg or anti-HBs. Of
our patients with MPA, 72% were positive for anti-HBs but
none were positive for HBsAg. In Korea, 56% of PAN patients
are positive for HBsAg or anti-HBs (12). HBV infection is
endemic in Korea, with 5.1% of men and 4.1% of women
in the 1998 Korean National Health and Nutrition Survey
being positive for HBsAg (13). In addition, the prevalence
of anti-HBs is high in Korea because of the global hepatitis
B vaccination program. These findings suggest that using
the presence of anti-HBs as a criterion for PAN would increase
the false positive rate in the diagnosis of PAN in Korea. When
we excluded individuals whose sole criterion for PAN was
positivity for anti-HBs, we found that 50% of MPA patients
satisfied the ACR criteria for PAN.
Combined therapy with high-dose steroids and cyclophos-
phamide has been indicated for patients with serious renal
or pulmonary disease (14). Of our patients, only one was treat-
ed with steroids without cyclophosphamide, whereas 17 were
treated with steroids and cyclophosphamide, making it dif-
ficult to compare treatment outcomes according to treatment
regimen.
Mortality from systemic vasculitis has been shown to be
significantly associated with disease severity, as assessed by
the FFS and the BVAS (3, 4, 14). However, we did not observe
significant relationships between mortality and these scoring
systems. While disease-related mortality in our study was
mainly associated with DAH, FFS does not reflect the latter.
The single most important prognostic factor in our study
was DAH (p=0.0016) (Fig. 2D). This finding is consistent
with previous reports showing that the relative risk of patient
death was 8.65 times greater in patients with pulmonary
hemorrhage (15).
To date, the efficacy of plasmapheresis in the treatment of
MPA is unproven. Although all patients with DAH were
treated with plasmapheresis in addition to steroids and/or
cyclophosphamide, with 4 patients (57%) showing an initial
response, 5 (71%) patients died during treatment. These find-
ings suggest that the addition of plasmapheresis to combina-
tion treatment with steroids and cyclophosphamide for life-
threatening DAH did not reduce mortality.
The overall mortality of our 18 patients with MPA was
56%, which was much higher than the 32.9% mortality rate
previously reported (3). We also found that our MPA patients
had a higher mortality rate than PAN patients in Korea (30%)
(12). Higher mortality rate observed in this study may have
been due to higher rate of DAH and the older age at onset.
The latter is supported by the observation that the mean age
at onset of non-survivors was higher than that of survivors
(67 vs. 57 yr).
In conclusion, we have shown here that the clinical mani-
festations of MPA in Korean patients had several distinguish-
ing features, including a higher rate of lung involvement, espe-
cially alveolar hemorrhage, which was the leading cause of
death in our patients. We also found that cardiac manifesta-
tions were more frequent and musculoskeletal pain and GI
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Manifestations
Serra et al. (16) Savage et al. (6) D’Agati et al. (17) Adu et al. (7) Guillevin et al. (3) Present 
1984 1985 1986 1987 1999 study
Number of patients 53 34 20 43 85 18
Mean age (yr) 53 50 49.6 56.8 62.4
Age range (yr) 3-76 14-73 6-80 19-77 22-83
M/F ratio 1.5 1.8 1 1.7 1.2 1
Constitutional symptoms 79 76 73 78
Fever 72 41 50 56 55 78
Renal 100 100 100 100 79 100
Musculoskeletal 74 72 33
Arthralgia 28 65 35 50 28
Myalgia 51 50 25 41 11
Skin 60 35 53 62 33
Pulmonary 55 55 34 25 72
Pulmonary hemorrhage 23 29 12 39
Pleural effusion 19 15 6 22
Gastrointestinal 51 56 30 28
Ears, nose, and throat 30 20 17
Neurologic 28 39
Peripheral neuropathy 19 18 15 14 58 39
Central nervous system 15 18 40 0 12 6
Cardiac 15 9 22
Table 5. Comparison of data from the present study with data from previous reportsinvolvements were less frequent in Korean MPA patients.
Moreover, our MPA patients were older at disease onset and
had a higher ANCA rate. Other overall clinical manifestations
did not differ significantly.
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